New drug cocktail aims to fight tough esophageal cancer
NCT ID NCT07554456
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study tests a new drug combination (BL-B01D1 plus tislelizumab, with or without 5-FU) against standard chemotherapy for people with advanced esophageal cancer that cannot be removed by surgery. About 90 adults will take part. The goal is to see if the new combo helps people live longer and shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.